Clearmind Medicine Inc (CMND)

$0.75 +0.01 (1.35%)
Market Cap 1.17M
Revenue (ttm) 0.00
Net Income (ttm) -3.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.48
Volume 681,900
Avg Vol 260,820
Day's Range N/A - N/A
Shares Out 1.50M
Stochastic %K 7%
Beta 1.51
Analysts Strong Buy
Price Target N/A

Company Profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as...

Industry: Biotechnology
Sector: Healthcare
Phone: 973 536 1016
Address:
1220 West 6th Avenue, Suite 101, Vancouver, Canada
MysticFortune
MysticFortune Mar. 18 at 12:23 AM
Ticker JAGU đź’Ž big news today, just getting found. Make sure to put JAGU on your watchlist. Beaten down IPO starting to reverse here. JAGU: âś…23M in cash âś…4$ IPO a month ago âś…No dilution filed âś…Positioned in a growing sector âś…Insiders shares are locked 6 months âś…Laguna salada project covers 230 000 hectares $EEIQ $CMND $SWMR $KRKR nice day ./.
0 · Reply
NathanWolffe
NathanWolffe Mar. 18 at 12:13 AM
Wednesday stocks on alert: $AIB (Old SGN + merger) 70% Beaten down. $YYGH (Unusual volume) $LNAI ( Squeeze potential) $CMND Back to 0.80$+ $JAGU Uranium Beaten down ipo, starting to reverse. 3$+
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 10:00 PM
$CMND Moves super thin Premarket Basically 2 mil floater at .68 cent Thats crazy $ARTL $BFAI
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 9:56 PM
$CMND Reminds me of $LHAI 1.4$ cash per share 2mil.float Way Undervalued
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:51 PM
$CMND 1.4 cash per share, 2 mil float at .60s is crazy cheap Way Undervalued ticker And pr today $MASK watching $AEHL 🌋 $XAIR ⏰️
1 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:46 PM
$CMND .72 break this will have a nice reversal
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:35 PM
$CMND Could pull a $UCAR move Nice pr
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:35 PM
$CMND Premarket potential Oversold and good news here
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 9:34 PM
$CMND Pr potential delayed run here Absolute bottom play $ARTL nice move $MASK.X watching again
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 9:33 PM
$CMND overnight idea
0 · Reply
Latest News on CMND
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

Mar 17, 2026, 9:15 AM EDT - 11 hours ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 16, 2026, 7:30 AM EDT - 1 day ago

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Mar 13, 2026, 7:45 AM EDT - 4 days ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Mar 11, 2026, 9:07 AM EDT - 6 days ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 11, 2026, 7:30 AM EDT - 6 days ago

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 7 days ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPRC

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Mar 4, 2026, 7:30 AM EST - 13 days ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Feb 19, 2026, 1:05 PM EST - 26 days ago

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Feb 9, 2026, 8:17 AM EST - 5 weeks ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Feb 6, 2026, 7:55 AM EST - 5 weeks ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Feb 3, 2026, 8:00 AM EST - 6 weeks ago

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Jan 20, 2026, 4:20 PM EST - 2 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Jan 14, 2026, 8:55 AM EST - 2 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 31, 2025, 9:10 AM EST - 2 months ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 24, 2025, 9:15 AM EST - 2 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 16, 2025, 8:45 AM EST - 3 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Dec 12, 2025, 8:32 AM EST - 3 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Dec 12, 2025, 6:32 AM EST - 3 months ago

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Dec 10, 2025, 4:15 PM EST - 3 months ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 5, 2025, 5:00 PM EST - 3 months ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Dec 2, 2025, 7:57 AM EST - 3 months ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Dec 1, 2025, 8:56 AM EST - 3 months ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Nov 25, 2025, 7:17 AM EST - 4 months ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Nov 24, 2025, 8:51 AM EST - 4 months ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 20, 2025, 6:01 AM EST - 4 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 4 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

SPRC

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 18, 2025, 8:56 AM EST - 4 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 17, 2025, 7:55 AM EST - 4 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Nov 13, 2025, 8:54 AM EST - 4 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Nov 12, 2025, 6:25 AM EST - 4 months ago

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 10, 2025, 8:07 AM EST - 4 months ago

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Nov 6, 2025, 4:02 PM EST - 4 months ago

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Nov 5, 2025, 6:55 AM EST - 4 months ago

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 30, 2025, 7:55 AM EDT - 4 months ago

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Oct 28, 2025, 8:08 AM EDT - 5 months ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Oct 27, 2025, 9:22 AM EDT - 5 months ago

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 21, 2025, 7:25 AM EDT - 5 months ago

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 5 months ago

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Sep 25, 2025, 7:40 AM EDT - 6 months ago

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Sep 19, 2025, 8:20 AM EDT - 6 months ago

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 7 months ago

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Aug 5, 2025, 8:15 AM EDT - 8 months ago

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:18 AM EDT - 8 months ago

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Jul 23, 2025, 8:55 AM EDT - 8 months ago

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Jul 15, 2025, 8:05 AM EDT - 8 months ago

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Jul 3, 2025, 8:47 AM EDT - 9 months ago

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Jun 30, 2025, 9:16 AM EDT - 9 months ago

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Jun 27, 2025, 9:00 AM EDT - 9 months ago

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

Jun 25, 2025, 7:48 AM EDT - 9 months ago

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

Jun 24, 2025, 8:06 AM EDT - 9 months ago

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

MysticFortune
MysticFortune Mar. 18 at 12:23 AM
Ticker JAGU đź’Ž big news today, just getting found. Make sure to put JAGU on your watchlist. Beaten down IPO starting to reverse here. JAGU: âś…23M in cash âś…4$ IPO a month ago âś…No dilution filed âś…Positioned in a growing sector âś…Insiders shares are locked 6 months âś…Laguna salada project covers 230 000 hectares $EEIQ $CMND $SWMR $KRKR nice day ./.
0 · Reply
NathanWolffe
NathanWolffe Mar. 18 at 12:13 AM
Wednesday stocks on alert: $AIB (Old SGN + merger) 70% Beaten down. $YYGH (Unusual volume) $LNAI ( Squeeze potential) $CMND Back to 0.80$+ $JAGU Uranium Beaten down ipo, starting to reverse. 3$+
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 10:00 PM
$CMND Moves super thin Premarket Basically 2 mil floater at .68 cent Thats crazy $ARTL $BFAI
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 9:56 PM
$CMND Reminds me of $LHAI 1.4$ cash per share 2mil.float Way Undervalued
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:51 PM
$CMND 1.4 cash per share, 2 mil float at .60s is crazy cheap Way Undervalued ticker And pr today $MASK watching $AEHL 🌋 $XAIR ⏰️
1 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:46 PM
$CMND .72 break this will have a nice reversal
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:35 PM
$CMND Could pull a $UCAR move Nice pr
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:35 PM
$CMND Premarket potential Oversold and good news here
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 9:34 PM
$CMND Pr potential delayed run here Absolute bottom play $ARTL nice move $MASK.X watching again
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 9:33 PM
$CMND overnight idea
0 · Reply
VK_10X
VK_10X Mar. 17 at 9:11 PM
$XAIR and $CMND
0 · Reply
GrindsToTheMax
GrindsToTheMax Mar. 17 at 9:06 PM
JAGU big news today, keep eyes on it. $CMND watching.
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 9:01 PM
$CMND Next potential runner like $VSME news potential delayed runner
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 8:59 PM
$CMND Patience here
0 · Reply
AlphaGalTrader
AlphaGalTrader Mar. 17 at 8:53 PM
$CMND I'll take a few.
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 8:52 PM
$CMND $MRLN $SWMR CMND low risk at absolute bottom adding Potential delayed run with news
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 8:50 PM
$CMND Adding more way Oversold with good pr
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 8:50 PM
$CMND Pr today and absolute bottom low floater Could see a nice reversal ⏰️🌋 $XAIR $BIAF watching
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 8:49 PM
$CMND Bottom play pr hit Potential delayed runner here at absolute bottom $YAAS $NTCL watching
0 · Reply
SPARTANVI
SPARTANVI Mar. 17 at 8:43 PM
$CMND wants reversal here
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 8:39 PM
$CMND like the risk reward Bottom play absolute lows on good news
0 · Reply
VENDETTA_One
VENDETTA_One Mar. 17 at 8:39 PM
$CMND added bottom play
0 · Reply